JP Morgan analyst Arun Jayaram maintains EOG Resources (NYSE:EOG) with a Overweight and lowers the price target from $156 to $153.
SELLAS Life Sciences To Present Data On Its Highly Selective CDK9 Inhibitor, GFH009, At The 2022 American Society Of Hematology Annual Meeting
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad
